Belgian drugmaker Galapagos NV has named former Johnson & Johnson senior executive Paul Stoffels as its CEO, effective from April 1, 2022.
Since 2012, Stoffels was the chief scientific officer at Johnson & Johnson and has spearheaded the development of its single-shot COVID-19 vaccine which won U.S. regulatory authorization in February 2021.
Towards the end of 2021, he retired from J&J and will replace current Galapagos CEO and co-founder Onno van de Stolpe after the latter’s planned retirement.
Stoffels also served on the Galapagos board of directors from its foundation in 1999 until 2002.
“Given his extraordinary R&D as well as managerial experience, extensive network, along with his deep understanding of Galapagos’ strengths and potential, we are convinced that Paul is uniquely qualified to lead Galapagos,” said Raj Parekh, chairman of Galapagos.
Galapagos develops treatments for inflammatory diseases and kidney ailments.
The company’s drug, filgotinib, has been approved for the European Union and some other markets to treat rheumatoid arthritis.
The company collaborated with Gilead Sciences on the drug’s development.